* Note: Prices are in Million (M) USD.
Description:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company based in Washington, D.C., focused on developing and commercializing innovative therapies for significant unmet medical needs, particularly in central nervous system and sleep disorders. The company boasts a robust pipeline of products and a commitment to advancing patient care through scientific expertise and strategic focus on niche markets. Vanda's dedication to enhancing patient outcomes positions it as a key player in the biopharmaceutical industry, with potential for sustainable growth and impactful contributions to healthcare.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $70 M
Debt : $6 M
EBITDA : $-102 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 20 overlapping fiscal years (max 20).Average Free Cash Flow: $-2 M
Average Revenue: $110 M
Revenue Converted To Free Cash Flow (%): -1.9%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $199 M
Revenue 5 Years Ago (2019-12-31): $227 M
Total Growth over 5 Years: -12.5%
5-Year Revenue CAGR (Historical): -2.6%
Forward 5-Year CAGR (Tapered): -2.4%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $58 M
Share Count 5 Years Ago (2020-12-31): $55 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-1.54
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-1.54
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 20 valid ROE years (max 20).Average ROE: -50.1%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $4.8
52-Week Low: $3.81
Threshold Price (15% Above 52-Week Low): $4.38
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $284 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2023-12-31): $0.21
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 7 points to above Vanda Pharmaceuticals Inc (VNDA) stock.
Last 4 Years Avg PE 32.07, Fair Value PE 9, Industry Based PE 15, Risk-Free Anchored PE (25% MoS) 18.47. Based on these 4 values, average assigned is 18.64. The fair value of Vanda Pharmaceuticals Inc (VNDA) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
